Arenas-Cabrera C, Cabezudo-García P, Calvo-Medina R, Galeano-Bilbao B, Martínez-Agredano P, Ruiz-Giménez J, Rodríguez-Uranga J J, Quiroga-Subirana P
Hospital Virgen del Rocío, Sevilla, España.
Hospital Regional Universitario de Málaga, Málaga, España.
Rev Neurol. 2024 Sep 16;79(6):161-173. doi: 10.33588/rn.7906.2024086.
This review, conducted by the Andalusian Epilepsy Society, provides an update on recent advances in the treatment of drug-resistant epilepsy, focusing on three new anti-seizure drugs: cenobamate, fenfluramine and cannabidiol. These emerging drugs offer new therapeutic alternatives for patients with drug-resistant focal epilepsy, Dravet syndrome, and Lennox-Gastaut syndrome. The primary objective of this review is to provide healthcare professionals with an up-to-date overview of the efficacy, safety and potential clinical applications of these treatments, backed by the latest evidence. In addition to reviewing the available clinical evidence, the document addresses essential practical considerations for the implementation of these drugs in routine clinical practice, including aspects such as their dosage, drug interactions, and management of their side-effects. With this review, the Andalusian Epilepsy Society aims to contribute to improving the care for and quality of life of patients with drug-resistant epilepsy and their families.
由安达卢西亚癫痫协会开展的本次综述，提供了耐药性癫痫治疗的最新进展，重点关注三种新型抗癫痫药物：司替戊醇、芬氟拉明和大麻二酚。这些新兴药物为耐药性局灶性癫痫、德雷维特综合征和伦诺克斯-加斯托综合征患者提供了新的治疗选择。本综述的主要目的是为医疗保健专业人员提供这些治疗方法的疗效、安全性和潜在临床应用的最新概述，并以最新证据为依据。除了综述现有的临床证据外，该文件还涉及在常规临床实践中使用这些药物的基本实际考虑因素，包括其剂量、药物相互作用以及副作用管理等方面。通过本次综述，安达卢西亚癫痫协会旨在为改善耐药性癫痫患者及其家庭的护理和生活质量做出贡献。
